Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan Amondys 45 Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MBP 241.0

    Amondys 45 (casimersen) coverage

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MBP 241.0 alerts

    Get alerted when Policy MBP 241.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for Amondys 45 (casimersen) for Geisinger Health Plan across commercial, Medicare, Medicaid, CHIP and exchange lines of business.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAmondys 45 (casimersen) coverage
    Policy CodePolicy MBP 241.0
    Change TypeNo material change
    Effective Date
    Last ReviewJan 7, 2026
    Next Review DateNov 17, 2025
    Key ActionObtain prior authorization from the Medical Director or designee with required genetic testing and motor function documentation for initial approval up to 6 months.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial authorization duration
    30 mg/kgMax FDA dose
    6MWTBaseline mobility doc
    InterdisciplinaryRequired specialties
    Exon 45Genetic requirement
    Policy Summary
    PayerGeisinger Health Plan
    PolicyAmondys 45 (casimersen) coverage
    Policy CodePolicy MBP 241.0
    Change TypeNo material change
    Effective Date
    Last ReviewJan 7, 2026
    Next Review DateNov 17, 2025
    Key ActionObtain prior authorization from the Medical Director or designee with required genetic testing and motor function documentation for initial approval up to 6 months.
    SourceLink
    On This Page
    Coverage Criteria for Amondys 45 (casimersen)Initial Therapy RequirementsCriteria for Continued CoverageRequired Tests and CodingProvider Actions, Prior Authorization, and DocumentationDefinitions and Key TermsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Amondys 45 (casimersen)

    Initial Therapy (Medicare/Medicaid)

    Medicare and Medicaid: Covered when ALL of the following are met

    Medicare/Medicaid initial criteria: Medical record documentation of interdisciplinary team involvement including, at a minimum, neurology, cardiology, pulmonology, and a genetic specialist; medical record documentation of Duchenne's muscular dystrophy (DMD) confirmed by genetic testing; medical record documentation that the member has a confirmed DMD gene mutation amenable to exon 45 skipping confirmed by a genetic counselor; medical record documentation of a baseline evaluation including a standardized assessment of motor function by a neurologist experienced in DMD; medical record documentation that Amondys 45 is being given concurrently with oral corticosteroids unless contraindicated or intolerant; medical record documentation that the patient will receive a dose consistent with FDA-approved labeling (maximum 30 mg/kg infused once weekly); medical record documentation that the patient has not received prior treatment with gene therapy (e.g., Elevidys)

    Initial approval up to 6 months

    Initial Therapy (Commercial/CHIP)

    Commercial, exchange, and CHIP: Covered when ALL of the following are met

    Commercial/CHIP initial criteria: Medical record documentation of interdisciplinary team involvement including, at a minimum, neurology, cardiology, pulmonology, and a genetic specialist; medical record documentation of Duchenne's muscular dystrophy (DMD) confirmed by genetic testing; medical record documentation that the member has a confirmed DMD gene mutation amenable to exon 45 skipping confirmed by a genetic counselor; medical record documentation of a baseline evaluation including a standardized assessment of motor function by a neurologist experienced in DMD; medical record documentation that Amondys 45 is being given concurrently with oral corticosteroids unless contraindicated or intolerant; medical record documentation that the patient will receive a dose consistent with FDA-approved labeling (maximum 30 mg/kg infused once weekly); medical record documentation that the patient is ambulatory as evidenced by a 6-Minute Walk Test (6MWT) within the past 3 months prior to initiation; medical record documentation that the patient has not received prior treatment with gene therapy (e.g., Elevidys)

    Initial approval up to 6 months

    Continuation Therapy / Renewal

    Subsequent approvals (all applicable lines of business): Covered when ALL of the following are met

    Renewal criteria: Medical record documentation that the member continues to benefit from treatment with casimersen; medical record documentation of an annual evaluation including assessment of motor function by a neurologist experienced in DMD; medical record documentation that Amondys 45 continues to be given concurrently with oral corticosteroids unless contraindicated or intolerant; medical record documentation that the patient will continue to receive a dose consistent with FDA-approved labeling (maximum 30 mg/kg infused once weekly); medical record documentation that the patient has not received prior treatment with gene therapy (e.g., Elevidys)

    Subsequent approvals for additional 6 months

    Commercial/CHIP mobility during renewal: For commercial, exchange, and CHIP lines: medical record documentation that the patient remains ambulatory as evidenced by a follow-up 6-Minute Walk Test (6MWT) within the past 6 months

    Reviewed for continued benefit

    Requests for Amondys 45 (casimersen) are ineligible for coverage when there is documentation that the patient has received prior gene therapy (for example, Elevidys). The policy requires medical record documentation that the patient has not received prior treatment with gene therapy as a condition of initial and subsequent approvals. Requests for members who show decline after prior gene therapy will be reviewed on a case‑by‑case basis.

    For commercial, exchange, and CHIP lines of business, initiation requests must include evidence of ambulatory status demonstrated by a 6‑Minute Walk Test (6MWT) within the past 3 months. Requests that lack this required baseline ambulatory documentation, or that do not include genetic confirmation of DMD and verification that the mutation is amenable to exon 45 skipping (confirmed by a genetic counselor), do not meet medical necessity criteria and may be denied.

    Initial Therapy Requirements

    Initial Therapy — Initial coverage requirements

    Initial coverage requirements

    Initial therapy nodes: Interdisciplinary team involvement (neurology, cardiology, pulmonology, genetic specialist); genetic confirmation of DMD and documentation that the mutation is amenable to exon 45 skipping confirmed by a genetic counselor; baseline standardized motor function assessment by a neurologist experienced in DMD; Amondys 45 to be given concurrently with oral corticosteroids unless contraindicated or intolerant; dosing consistent with FDA labeling (maximum 30 mg/kg IV once weekly); for commercial/CHIP patients, documented ambulatory status with a 6-Minute Walk Test (6MWT) within the prior 3 months; documentation that the patient has not received prior gene therapy (e.g., Elevidys)

    Prior authorization required; initial approval up to 6 months

    Criteria for Continued Coverage

    Continuation Therapy — Criteria for continued coverage (renewal)

    Criteria for continued coverage (renewal)

    Renewal nodes: Documentation that the member continues to benefit from casimersen; annual neurologist evaluation including assessment of motor function; continued concurrent oral corticosteroids unless contraindicated or intolerant; continued dosing consistent with FDA labeling (maximum 30 mg/kg infused once weekly); documentation that the patient has not received prior gene therapy (e.g., Elevidys)

    Subsequent approvals for 6 months

    Commercial/CHIP ambulatory requirement for renewal: For commercial, exchange, and CHIP lines: documentation that the patient remains ambulatory as evidenced by a follow-up 6-Minute Walk Test (6MWT) within the past 6 months

    Used to assess continued benefit

    Required Tests and Coding

    6-Minute Walk Test (6MWT) — Timing requirements
    Baseline timing for initiation (Commercial/CHIP)6-Minute Walk Test (6MWT) performed within the past 3 months prior to initiation
    Follow-up timing for renewal (Commercial/CHIP)Follow-up 6MWT documented within the past 6 months to demonstrate continued ambulatory status for renewal
    Applicability6MWT requirement applies to commercial, exchange, and CHIP lines of business for initiation and renewal mobility assessment

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; initial approvals up to 6 months

    Prior authorization is required and must be obtained from the Medical Director or their designee. Initial approvals will be granted for up to 6 months (or less if the reviewer determines medically appropriate) and require submission of the specified clinical documentation listed in the policy (see genetic testing, motor function assessment, interdisciplinary team documentation, dosing consistent with FDA labeling, and documentation of no prior gene therapy). Subsequent approvals are for additional 6-month periods and require evidence of continued benefit and required follow-up documentation.

    • Obtain prior authorization from the Medical Director or designee before initiation.
    • Initial authorization duration: up to 6 months (may be shorter if medically appropriate).
    • Subsequent approvals: additional 6 months and require documentation of continued benefit and annual/interval assessments as specified.
    Step Therapy

    No specified step therapy; document no prior gene therapy

    Definitions and Key Terms

    Casimersen — Definition and mechanism
    Drug name (generic/brand)Casimersen (Amondys 45)
    Mechanism summaryAntisense oligonucleotide designed to bind exon 45 of dystrophin pre-mRNA, resulting in skipping of exon 45 during mRNA processing
    Therapeutic effectExon 45 skipping allows production of an internally truncated dystrophin protein in patients with mutations amenable to exon 45 skipping
    Regulatory status noteApproved under accelerated approval based on increased dystrophin production; continued approval may depend on verification of clinical benefit in confirmatory trials
    Medical Necessity — Definition and applicability
    DefinitionMedical Necessity: services the Plan determines are appropriate for the symptoms and diagnosis or treatment of the member's condition, provided for direct care, in accordance with current medical standards, not primarily for convenience, and the most appropriate level of service

    Background

    Casimersen (Amondys 45) is an antisense oligonucleotide designed to bind exon 45 of dystrophin pre‑mRNA to induce exon 45 skipping and enable production of an internally truncated dystrophin protein in patients with Duchenne muscular dystrophy whose mutations are amenable to exon 45 skipping. The agent is approved under accelerated approval based on increased dystrophin production; ongoing coverage requires documentation consistent with the FDA labeling, including dosing not to exceed 30 mg/kg once weekly, and clinical monitoring to verify continued benefit.

    No specific step therapy sequence is specified in the policy; however, the medical record must document that the patient has not previously received gene therapy (for example, Elevidys) to be eligible.

    • Policy does not require trials of alternative agents prior to casimersen.
    • Document explicitly that the patient has not had prior gene therapy (e.g., Elevidys).
    Documentation Required

    Required medical record documentation and assessments

    Medical record documentation must include interdisciplinary team involvement, genetic confirmation and counseling, baseline and follow-up motor function assessments, corticosteroid use status, dosing consistent with FDA labeling, ambulatory status (for commercial/CHIP), and documentation of no prior gene therapy.

    • Interdisciplinary team involvement including at minimum neurology, cardiology, pulmonology, and a genetic specialist (e.g., geneticist or genetic counselor).
    • Genetic confirmation of DMD and documentation that the mutation is amenable to exon 45 skipping (confirmed by a genetic counselor).
    • Baseline standardized motor function assessment by a neurologist experienced in DMD; for initiation (commercial/CHIP) include a 6MWT within the past 3 months.
    • For renewals, annual neurologist evaluation including motor function assessment and, for commercial/CHIP, a follow-up 6MWT within the past 6 months.
    • Documentation that Amondys 45 is given concurrently with oral corticosteroids unless contraindicated or intolerant.
    • Documentation that dosing will be consistent with FDA labeling (maximum 30 mg/kg infused once weekly).
    • Documentation that the patient has not received prior gene therapy (e.g., Elevidys).
    Denial Risk

    Grounds for denial: missing or nonconforming documentation and ineligible mutation/history

    Requests may be denied if required documentation is missing or if DMD is not confirmed by genetic testing or the mutation is not amenable to exon 45 skipping; other common denial triggers include absent baseline/renewal motor function assessments, lack of documented concurrent corticosteroid use when applicable, dosing inconsistent with FDA labeling, or prior receipt of gene therapy.

    • Missing interdisciplinary team documentation (neurology, cardiology, pulmonology, genetic specialist).
    • No genetic confirmation of DMD or no documentation that the mutation is amenable to exon 45 skipping (as confirmed by a genetic counselor).
    • Absence of baseline standardized motor function assessment (or required 6MWT for commercial/CHIP) within specified timeframes.
    • Failure to document concurrent oral corticosteroid therapy unless contraindicated or intolerant.
    • Dosing not consistent with FDA-approved labeling (maximum 30 mg/kg weekly).
    • Documentation showing prior treatment with gene therapy (e.g., Elevidys).
    Application to Amondys 45Coverage and prior authorization decisions require documentation that treatment meets medical necessity criteria (appropriate diagnosis, direct care, current standards) as outlined in the policy
    Documentation expectationsMedical record must include genetic confirmation of DMD and exon 45 amenable mutation, interdisciplinary team involvement, baseline motor function assessment, ambulatory documentation (6MWT where required), and dosing consistent with FDA labeling